Pfizer's latest $10 billion buyback suggests scant interest in deals
This article was originally published in Scrip
Since taking over as CEO in December 2010, Pfizer’s Ian Read has made his view on stock buybacks very clear: Buying back Pfizer’s own stock is a better use of the company’s cash than doing acquisitions.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.